Clinical trials: Dyskinesia, Drug-Induced
Tardive Dyskinesia
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive dyskinesia in subjects with schizophrenia or…
- Trial name
- NCT01393600
- Testing
- NBI-98854
- Where
- 11 sites in United States
- Volunteers
- 37 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease, Dyskinesia, Drug-Induced
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.
- Trial name
- STAT-PD (NCT04064294)
- Testing
- Intravenous Infusion
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Tardive Dyskinesia, Huntington Disease
Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy…
- Trial name
- NCT06216054
- Testing
- LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Dystonia, Movement Disorder
Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
The purpose of this randomized, double blind, multi-center study is to assess the efficacy and safety of bilateral pallidal deep brain stimulation in patients with tardive dystonia.
- Trial name
- NCT00331669
- Testing
- deep brain stimulation
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Xenazine in Late Dyskinetic Syndrome With Neuroleptics
Late dyskinetic syndrome with neuroleptics, or tardive dyskinesia, is the appearance of abnormal involuntary movements (AIM) in patients treated with antipsychotics for at least three months.
- Trial name
- Xeladys (NCT01543321)
- Testing
- Tetrabenazine
- Where
- 19 sites in France
- Volunteers
- 54 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Dyskinesia, Schizophrenia
Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
Tardive dyskinesia is a common complication of conventional antipsychotic treatment in subjects with schizophrenia. This study investigates whether the addition of the omega-3 fatty acid, ethyl-eicosapentaenoic acid (EPA) to…
- Trial name
- NCT00114595
- Testing
- eicosapentaenoic acid
- Where
- South Africa
- Volunteers
- 84 people
- Sponsor
- University of Stellenbosch
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD)…
- Trial name
- TOP-DYSK (NCT01789047)
- Testing
- Topiramate, Amantadine
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Dyskinesia, Medication-induced
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00175955
- Testing
- Levetiracetam
- Where
- 7 sites in Belgium, Bulgaria
- Volunteers
- 70 people
- Sponsor
- UCB Pharma
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Tardive Dyskinesia, Intellectual Disability
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population.
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06997198)
- Testing
- Deutetrabenazine Oral Capsule
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University Hospitals Cleveland Medical Center
Tardive Dyskinesia
Levetiracetam Treatment of Tardive Dyskinesia
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.
- Trial name
- NCT00291213
- Testing
- levetiracetam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Dystonia, Drug Induced Dystonia
Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
This research involves retrospective and prospective studies for clinical validation of a DystoniaNet deep learning platform for the diagnosis of isolated dystonia.
- Conditions
- Dystonia, Drug Induced Dystonia, Parkinson Disease, Essential Tremor
- Trial name
- NCT05317390
- Testing
- DystoniaNet-based diagnosis of isolated dystonia
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Parkinson Disease, Dyskinesia, Medication-Induced
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
This is a randomized, double-blind, placebo-controlled, crossover, proof-of-concept Phase 2 study to test efficacy and safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease subjects with levodopa-induced dyskinesia.
- Conditions
- Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use
- Trial name
- NCT04147949
- Testing
- AV-101
- Volunteers
- 20 people
- Sponsor
- VistaGen Therapeutics, Inc.
Tardive Dyskinesia
Pyridoxal Kinase Activity in Tardive Dyskinesia
Objectives: The mechanisms of tardive dyskinesia (TD) remain unclear, although pathophysiologic theories have proposed mechanisms such as dopamine receptor supersensitivity, the degeneration of cholinergic striatal interneurons…
- Trial name
- NCT01908452
- Testing
- Pyridoxine
- Where
- 3 sites in Israel
- Sponsor
- Beersheva Mental Health Center
Dyskinesia, Medication-Induced, Parkinson's Disease
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)
This is a randomized sham-controlled double-blind study to test the hypothesis that transcranial static magnetic field stimulation (tSMS) of the motor cortex improves levodopa-induced dyskinesias in patients with Parkinson's…
- Trial name
- NCT02657681
- Testing
- tSMS
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundación de investigación HM
Huntington Disease, Tardive Dyskinesia
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
This is a A single-center, randomized, open-label, two-dose, two-period, crossover trial was conducted to evaluate the effect of food on the Pharmacokinetic characteristics and safety of oral administration of LPM3770164…
- Trial name
- NCT06474650
- Testing
- LPM3770164 sustained release tablet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Fibromyalgia, Mitochondrial Diseases
Heart Rate Variability in Response to Metformin Challenge
Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use).
- Conditions
- Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
- Trial name
- NCT02500628
- Testing
- Metformin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Woodinville Psychiatric Associates
Dyskinesia, Drug-Induced
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
This study will assess the risk of experiencing tardive dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients.
- Trial name
- NCT00255879
- Testing
- Quetiapine, Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Diego
Akathisia
Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation
Akathisia is a movement disorder that is often a side effect of certain psychiatric drugs. People with akathisia are unable to sit or keep still, complain of restlessness, fidget, rock from foot to foot, and pace.
- Trial name
- NCT00065286
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)